Gut metabolites and functional recovery after ischemic stroke: a genetic perspective.

The current study explores the relationship between genetically predicted gut metabolites and functional outcomes following ischemic stroke, utilizing the Mendelian Randomization (MR) framework. Genetic information regarding gut microbiota-derived metabolites was sourced from 2076 participants of European descent participating in the Framingham Heart Study. Data on functional outcomes 90 days post-ischemic stroke were acquired from the Genetics of Ischemic Stroke Functional Outcomes Network (n = 6,021).

Exploring the role of traditional Chinese medicine rehabilitation in stroke based on microRNA-mediated pyroptosis: A review.

Stroke, also known as "cerebrovascular accident," is a disease caused by acute impairment of brain circulation, which has a high rate of disability and mortality. Ischemic stroke (IS) is the most common type of stroke and a major cause of death and disability worldwide. At present, there are still many limitations in the treatment of IS, so it may be urgent to explore more treatments for IS.

Exploring the biological basis of acupuncture treatment for traumatic brain injury: a review of evidence from animal models.

Traumatic brain injury (TBI) occurs when external physical forces impact the brain, potentially causing long-term issues such as post-traumatic stress disorders and cognitive and physical dysfunctions. The diverse nature of TBI pathology and treatment has led to a rapid acceleration in research on its biological mechanisms over the past decade. This surge presents challenges in assessing, managing, and predicting outcomes for TBI cases.

Broadly neutralizing antibodies to combat influenza virus infection.

The diversified classification and continuous alteration of influenza viruses underscore for antivirals and vaccines that can counter a broad range of influenza subtypes. Hemagglutinin (HA) and neuraminidase (NA) are two principle viral surface targets for broadly neutralizing antibodies. A series of monoclonal antibodies, targeting HA and NA, have been discovered and characterized with a wide range of neutralizing activity against influenza viruses.